Monopoly considerations push FTC to sue to dam Amgen’s greater than $26B deal for Horizon
The U.S. is making an attempt to dam a proposed $26 billion acquisition of Horizon Therapeutics by biotech drug developer Amgen on antitrust grounds.
The Federal Trade Commission stated Tuesday that the deal, introduced in December, would give Amgen unfair leverage to dam competitors for Horizon medicines....